OmniComm Systems, Inc. Responds to Industry's Growing Demand for Integrated Electronic Data Capture (EDC) Solutions and Signs 15 New Deals in Second Quarter 2007
FT. LAUDERDALE, FL, July 23, 2007-/MarketWire/-OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that they have closed 15 new business deals in Q2, 2007. Key market segments for the new business include pharmaceutical, medical device, contract research organizations (CRO) and academic medical center customers, including a high profile Top 50 pharmaceutical company. TrialMaster will be implemented in both an ASP, fully hosted environment for the new trials and also in 2 new Technology Transfer deployments for those clients that want to bring EDC in-house.
OmniComm’s Sr. Vice President of Business Development, Stephen Johnson, commented, “The company’s escalating growth is a direct result of the drug development industry’s need for flexible and integrated solutions for clinical trials. TrialMaster provides sponsors with a feature rich EDC product that is easy to use, easy to integrate with and is not laden with hidden or exorbitant costs.” Added Johnson, “Our Support and Consulting Services groups are made up of industry veterans that stand ready to deliver quality driven solutions and support for our customers using EDC.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Carvykti Significantly Boosts Survival, MRD Negativity in Relapsed Multiple Myeloma
December 10th 2024Phase III CARTITUDE-4 trial shows Carvykti significantly improves minimal residual disease negativity rates, progression-free survival, and overall survival compared to standard therapies for patients with relapsed or refractory multiple myeloma, especially when used earlier in treatment.